Long-Term Complications of Antineoplastic Agents

Praga C. , Beretta G. , Vigo PL , et al: Adriamycin cardiotoxicity: A survey of 1,273 patients. Cancer Treat Rep 63:827-834, 1979

Von Hoff DD , Layard MW , Basa P. , et al: Risk factors for doxorubicin-induced congestive heart failure . Ann Intern Med 91:710-717, 1979

Von Hoff DD , Rozencweig M. , Layard M. , et al: Daunomycin-induced cardiotoxicity in children and adults: A review of 110 cases. Am J Med 62:200-208, 1977

Saltiel E. , McGuire W. : Doxorubicin (Adriamycin) cardiomyopathy. West J Med 139:332-341, 1983

Buzdar AU , Marcus C. , Smith TL , et al: Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 55: 2761-2765, 1985

Billingham ME , Mason GW , Bristow MR , et al: Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62:865-872, 1978

Ferrans VJ : Overview of cardiac pathology in relation to anthracycline cardiotoxicity . Cancer Treat Rep 62:955-961, 1978

Bristow MR , Mason JW , Billingham ME , et al: Dose-effect and structure function relationships in doxorubicin cardiomyopathy. Am Heart J 102:709-718, 1981

Bachur NR , Gordon SL , Gee MV : A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer 38:1745-1752, 1977

Myers CE , Chabner BA : Anthracyclines, in Chabner BA , Collins JM (eds): Cancer Chemotherapy Principles and Practice. Philadelphia, PA, Lippincott, 1990, pp 356-381

Demant Ejf , Nørskov-Lauritsen N. : Binding of transferrin-iron by adriamycin at acidic Ph. FEBS Lett 196:321-324,1986

Thomas CE , Aust SE : Release of iron from ferritin by cardiotoxic anthracycline antibiotics . Arch Biochem Biophys 248:684-695, 1986

Myers CE , Gianni L. , Zweier J. , et al: The role of iron in adriamycin biochemistry. Fed Proc 45:2792-2797, 1986 14. Myers CE , Liss RH , Ifrim J. , et al: The role of lipid peroxidation on cardiac toxicity and tumor response. Science 197:165-167,1977

Doroshow JH : Effect of anthracycline antibiotics on oxygen radical formation in the rat heart. Cancer Res 43:460-472, 1983

Singal PK , Pierce GN : Adriamycin stimulates low-affinity Ca2+ binding and lipid peroxidation by depresses cardiac function. Am J Physiol 250:H419-H425, 1986

Griffin-Green EA , Zaleska MM , Ericinska M. : Adriamycin-induced lipid peroxidation in mitochondria and microsomes. Biochem Pharmacol 37:3071-3077,1988

Doroshow JH , Locker GH , Myers CE : Enzymatic defenses of the mouse heart against reactive oxygen metabolites: Alterations produced by doxorubicin. J Clin Invest 65:128-135,1980

Goodman J. , Hochstein P. : Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin. Biochem Biophys Res Commun 77:797-803, 1977

Billingham ME , Bristow MR , Glatstein E. , et al: Adriamycin cardiotoxicity: Endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol 1:17-23,1977

Minow RA , Benjamin RS , Gottlieb JA : Adriamycin (NSC-123127) cardiomyopathy: An overview with determination of risk factors. Cancer Treat Rep 6:195-201, 1975

Piver MS , Marchetti DL , Parthasarathy KL , et al: Doxorubicin hydrochloride (Adriamycin) cardiotoxicity evaluated by sequential radionuclide angiography. Cancer 56:76-80, 1985

Dukart G. , Posner L. , Henry D. , et al: Comparative cardiotoxicity of motoxantrone vs. doxorubicin. Proc Am Soc Clin Oncol 5:48, 1986 (abstr)

Kharasch ED , Novak RF : Inhibition of adriamycin-stimulated microsomal lipid peroxidation by mitoxantrone and amentantrone. Biochem Biophys Res Commun 108: 1346-1352, 1982

Butler J. , Hoey BM : Are reduced quinones necessarily involved in the antitumour activity of quinone drugs? Br J Cancer 55:53-59, 1987 (suppl)

Clark GM , Tokaz LK , von Hoff DD , et al: Cardiotoxicity in patients treated with mitoxantrone on Southwest Oncology Group phase II protocols. Cancer Treat Symp 3:25-30,1984

Aapro MS , Alberts DS , Woolfenden JM , et al: Prospective study of left ventricular function using radionuclide scans in patients receiving mitoxantrone. Invest New Drugs 1:341-347, 1983

Unverferth DV , Underferth BJ , Balcerzak SP , et al: Cardiac evaluation of mitoxantrone . Cancer Treat Rep 67:343-350, 1983

Prai GR , Reed NS , Ruddell NS : A case of mitoxantrone-associated cardiomyopathy without prior anthracycline therapy. Br J Radiol 60:1125-1126, 1987

Crossley RJ : Clinical safety and tolerance of mitoxantrone . Semin Oncol 11:54-58, 1984 (suppl)

Skenkenberg TD , Von Hoff DD: Mitoxantrone: A new anticancer drug with significant clinical activity. Ann Intern Med 105:67-81, 1986

Gottdiener JS , Appelbaum FR , Ferrans FJ , et al: Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 141:758-763, 1981

Buckner CD , Rudolph RJ , Fefer A. , et al: High dose cyclophosphamide therapy for malignant disease. Cancer 29:357-365, 1972

Colvin M. , Chabner BA : Alkylating agents, in Chabner BA , Collins JM (eds): Cancer Chemotherapy Principles and Practice. Philadelphia, PA, Lippincott, 1990, pp 276-313

Applebaum FR , Strauchen JA , Graw RG : Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity. Lancet 1:58-62, 1976

Cazin B. , Gorin NC , Laporte JP , et al: Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations. Cancer 57:2061-2069,1986

Weiss RB , Grillo-Lopez AJ , Marsoni S. , et al: Amsacrine-associated cardiotoxicity: An analysis of 82 cases . J Clin Oncol 4:918-928, 1986

Lowe MC : In vitro evaluation of the cardiotoxic potential of AMSA. Cancer Treat Rep 66:1571-1573, 1982

Venveij J. , van der Burg ME , Pinedo HM : Mitomycin C-induced hemolytic uremic syndrome. Six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drug . Radiother Oncol 8:33-41, 1987

Buzdar AU , Legha SW , Tashima CK , et al: Adriamycin and mitomycin C: Possible synergistic cardiotoxicity . Cancer Treat Rep 62:1005-1008, 1978

Bristow MR , Lopez MB , Jason JW , et al: Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer 50:32-41, 1982

Schwartz RG , McKenzie WB , Alexander J. , et al: Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: Seven-year experience using serial radionuclide angiocardiography. Am J Med 82:1109-1118, 1987

Vorobiof DA , Iturralde M. , Falkson G. : Amsacrine cardiotoxicity: Assessment of ventricular function by radionuclide angiography. Cancer Treat Rep 67:1115-1117, 1983 44. Legha SS , Benjamin RS , Mackay B. , et al: Reduction of doxorubicin cardiotoxicity by prolonged continuous infusion. Ann Intern Med 66:13-139, 1982

Valdivieso M. , Burgess MA , Ewer MS , et al: Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: A prospective, randomized study. J Clin Oncol 2:207-214, 1984

Torti FM , Bristow MR , Howes AE , et at: Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule: Assessment by endomyocardial biopsy. Ann Intern Med 99:745-749, 1983

Saltiel E. , McGuire W. : Doxorubicin (Adriamycin) cardiomyopathy: A critical review. West J Med 139:332-341, 1983

Myers CE , Gianni L. , Simone CB , et al: Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. Biochemistry 21:1707-1712, 1982

Speyer JL , Green MD , Kramer E. , et al: Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer . N Engl J Med 319:745-752, 1988

Saini J. , Rich MW , Lyss AP : Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity . Ann Intern Med 106:814-816, 1987

Gross NJ : Pulmonary effects of radiation therapy. Ann Intern Med 86:81-92,1977

O'Driscoll BR , Hasleton PS , Taylor PM , et al: Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood . N Engl J Med 323:378-382,1990

Weiss T. , Poster D. , Penta J. : The nitrosoureas and pulmonary toxicity. Cancer Treat Rev 8:111-125,1981

Cordonnier C. , Vernant JP , Mital P. , et al: Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia. Cancer 51:1814-1818, 1983

Heard BE , Cooke RA : Busulfan lung. Thorax 23:187-193, 1968

Burns WA , McFarland W. , Matthews MJ : Busulfan-induced pulmonary disease. Report of a case and review of the literature . Am Rev Respir Dis 101:408-413, 1970

Mark GJ , Lehimgar-Zadeh A. , Ragsdale BD : Cyclophosphamide pneumonitis. Thorax 33:89-93, 1978

Patel AR , Shah. PC , Rhee HL , et al: Cyclophosphamide therapy and interstitial pulmonary fibrosis . Cancer 38:1542-1549, 1976

Cole SR , Myers TJ , Klatsky AU : Pulmonary disease with chlorambucil therapy. Cancer 41:455-459, 1978

Godard PH , Marty JP , Michel FB : Interstitial pneumonia and chlorambucil. Chest 76:471-3, 1979

Westerfield BT , Michalski JP , McCombs C. , et al: Reversible melphalan-induced lung damage. Am J Med 68:767-771, 1980

Goucher G. , Rowland V. , Hawkins J. : Melphalan-induced pulmonary interstitial fibrosis. Chest 77:805-806, 1980

Venveij J. , van Zanten T. , Souren T. , et al: Prospective study on the dose relationship of mitomycin C-induced interstitial pneumonitis. Cancer 60:756-761, 1987

Chang AY , Kuebler JP , Pandya KJ , et al: Pulmonary toxicity induced by mitomycin C is highly responsive to glucocorticoids. Cancer 57:2285-2290, 1986

Gunstream SR , Seidenfeld JJ , Sobonya RE , et al: Mitomycin-associated lung disease . Cancer Treat Rep 67: 301-304, 1983

St Clair EW , Rice JR , Snyderman R. : Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis. Arch Intern Med 145:2035-2038, 1985

Phillips TJ , Jones DH , Baker H. : Pulmonary complications following methotrexate therapy. J Am Acad Dermatol 16:373-375; 1987

Haupt HM , Hutchins GM , Moore GW : Ara-C lung: Noncardiogenic pulmonary edema complicating cytosine arabinoside therapy of leukemia. Am J Med 70:256-261, 1981

Konits PH , Aisner J. , Sutherland JC , et al: Possible pulmonary toxicity secondary to vinblastine. Cancer 50:2771-2774, 1982

Jones SE , Moore M. , Blank N. , et al: Hypersensitivity to procarbazine (Matulane) manifested by fever and pleuropulmonary reaction. Cancer 29:498-500, 1972

Freeman BA , Crapo JD : Biology of disease: Free radicals and tissue injury. Lab Invest 47:412-426, 1982

Lewis RA , Austen KF : The biologically active leukotrienes: Biosynthesis, metabolism, receptors, functions and pharmacology. J Clin Invest 73:889-897, 1984

Cooper JA , White DA , Matthay RA : Drug-induced pulmonary disease: Part 1: Cytotoxic drugs. Am Rev Respir Dis 133:321-340, 1986

L'age-Stehr J. , Diamanstein T. : Induction of autoreactive T lymphocytes and their suppressor cells by cyclophosphamide. Nature 271:663-665, 1978

Absher M. , Hildebran J. , Trombley L. , et al: Characteristics of cultured lung fibroblasts from bleomycin-treated rats. Comparison with in vitro exposed normal fibroblasts. Am Rev Respir Dis 129:125-129,1984

Holoye PY , Luna MA , MacKay B. , et al: Bleomycin hypersensitivity pneumonitis. Ann Intern Med 88:47-49, 1978

Blum RH , Carter SK , Agre K. : A clinical review of bleomycin—A new antineoplastic agent. Cancer 31:903-914, 1973

Einhorn L. , Krause M, Hornback , et al: Enhanced pulmonary toxicity with bleomycin and radiotherapy in oat cell lung cancer. Cancer 37:2414-2416, 1976

Samuels ML , Johnson De , Holoye PY , et al: Large-dose bleomycin therapy and pulmonary toxicity. A possible role of prior radiotherapy. JAMA 235:1117-1120, 1976

Goldiner PL , Carlon GC , Cvitkovic E. , et al: Factors influencing postoperative morbidity and mortality in patients treated with bleomycin. Br Med J 1:1664-1667, 1978

Parvinen LM , Kilkku P. , Makinen E. , et al: Factors affecting the pulmonary toxicity of bleomycin. Acta Radiol 22:417-421, 1983

Bauer KA , Skarin AT , Balikian JP , et al: Pulmonary complications associated with combination chemotherapy programs containing bleomycin. Am J Med 74:557-563, 1983

Perry DJ , Weiss RB , Taylor HG : Enhanced bleomycin toxicity during acute renal failure. Cancer Treat Rep 66:592-593,1982

Bechard DE , Fairman RP , DeBlois GG , et al: Fatal pulmonary fibrosis from low-dose bleomycin therapy. South Med J 80:646-649, 1987

Iacovino JR , Leitner J. , Abbas AK , et al: Fatal pulmonary reaction from low doses of bleomycin. An idiosyncratic tissue response. JAMA 235:1253-1255,1976

De Lena M. , Guzzon A. , Monfardini S. , et al: Clinical, radiologic, and histopathologic studies on pulmonary toxicity induced by treatment with bleomycin (NSC-125066). Cancer Chemother Rep 56:343-356, 1972

Ginsberg SJ , Comis RL : The pulmonary toxicity of antineoplastic agents. Semin Oncol 9:34-51, 1982

Chabner BA : Bleomycin, in Chabner BA , Collins JM (eds): Cancer Chemotherapy Principles and Practice. Philadelphia, PA, Lippincott, 1990, pp 341-355

Dineen MK , Englander LS , Huben RP : Bleomycin-induced nodular pulmonary fibrosis masquerading as metastatic tesiicular cancer. J Urol 136:473-475, 1986

Pascual RS , Mosher MB , Sikand RS , et al: Effects of bleomycin on pulmonary function in man. Am Rev Respir Dis 108:211-217, 1973

Van Barneveld PW , Van der Mark TW , Sleijfer DT , et al: Predictive factors for bleomycin-induced pneumonitis. Am Rev Respir Dis 130:1078-1081, 1984

Conley NS , Yarbro JW , Ferrari HA , et al: Bleomycin increases superoxide anion generation by pig peripheral alveolar macrophages. Mol Pharmacol 30:48-52, 1986

Ishizuka M. , Takayama H. , Takeuchi T. , et al: Activity and toxicity of bleomycin. J Antibiot (Tokyo) 20:15-24,1967

Ohnuma T. , Holland JF , Masuda H. , et al: Microbiological assay of bleomycin: Inactivation, tissue distribution, and clearance. Cancer 33:1230-1238, 1974

Filderman AE , Genovese LA , Lazo JS : Alterations in pulmonary protective enzymes following systemic bleomycin treatment in mice. Biochem Pharmacol 37:1111-1116, 1988

Breul SD , Bradley KH , Hance AJ , et al: Control of collagen production by human diploid lung fibroblasts . J Biol Chem 255:5250-5260,1980

Lee W. , Moore RP , Wampler GL : Interstitial pulmonary fibrosis as a complication of prolonged methyl-CCNU therapy. Cancer Treat Rep 62:1355-1358, 1978

Koss LG , Melamet MR , Mayer K. The effect of busulfan on human epithelia. Am J Clin Pathol 44:385-397, 1965

Codling BW , Chakera Tmh : Pulmonary fibrosis following therapy with melphalan for multiple myeloma . J Clin Pathol 25:668-673, 1972

Maxwell I. : Reversible pulmonary edema following cyclophosphamide treatment. JAMA 229:137-138, 1974

Abdel Karim FW , Ayash RE , Allam C. , et al: Pulmonary fibrosis after prolonged treatment with low-dose cyclophosphamide. A case report. Oncology 40:174-176, 1983

Carson CW , Cannon CW , Egger JM , et al: Pulmonary disease during the treatment of rheumatoid arthritis with low-dose pulse methotrexate. Semin Arthritis Rheum 16:186-195,1987

Sostman HD , Matthay RA , Putman C. , et al: Methotrexate-induced pneumonitis. Medicine 55:371-388, 1976 104. From E. : Methotrexate pneumonitis in a psoriatic. Br J Derm 93:107-110, 1975

Everts CS , Westcott JL , Bragg DG : Methotrexate therapy and pulmonary disease. Radiology 107:539-543, 1973

Allegra CJ : Antifolates, in Chabner BA , Collins JM (eds): Cancer Chemotherapy Principles and Practice. Philadelphia, PA, Lippincott, 1990, pp 110-153

Klein DS , Wilds PR : Pulmonary toxicity of antineoplastic agents: Anaesthetic and postoperative implications. Can Anaesth Soc J 30:399-405, 1983

Sikic BI , Collins JM , Mimmnaugh EG , et al: Improved therapeutic index of bleomycin when administered by continuous infusion in mice. Cancer Treat Rep 62:2011-2017,1978

Crystal RG , Gadek JE , Ferrans VJ , et al: Interstitial lung disease: Current concepts of pathogenesis, staging and therapy. Am J Med 70:542-568,1981

Weber BL , Tanyer G. , Poplack DG , et al: Transient acute hepatotoxicity of high-dose methotrexate therapy during childhood. NCI Monogr 5:207-212, 1987

Paulus HE : FDA arthritis advisory committee meeting: Methotrexate; Guidelines for the clinical evaluation of antiinflammatory drugs; DMSO in scleroderma . Arthritis Rheum 29:1289-1290,1986

Zachariae H. , Kragballe K. , Søgaard H. : Methotrexate-induced cirrhosis. Br J Dermatol 102:407-412, 1980

Dahl MG , Gregory MM , Scheuer PJ : Liver damage due to methotrexate in patients with psoriasis. Br Med J 1:625-630, 1971

Tolman KG , Clegg DO , Lee RG , et al: Methotrexate and the liver. J Rheumatol 12:29-34, 1985 (suppl)

Weinstein GD , Cox JW , Suringa DW , et al: Evaluation of possible chronic hepatotoxicity from methotrexate for psoriasis. Arch Derm 102:613-618, 1970

Reynolds FS , Lee WM : Hepatotoxicity after long-term methotrexate therapy. South Med J 79:536-539,1988

Einhorn M. , Davidsohn I. : Hepatotoxicity of 6-mercaptopurine . JAMA 188:802-806, 1964

Key NS , Emerson PM , Allan NC , et al: Oesophageal varices associated with busulphan-thioguanine combination therapy for chronic myeloid leukemia. Lancet 2:1050-1052, 1987

Clark PA , Hsia YE , Huntsman RG : Toxic complications of treatment with 6-mercaptopurine: Two cases with hepatic necrosis and intestinal ulceration. Br Med J 1:393-395, 1960

Perry MC : Hepatotoxicity of chemotherapeutic agents. Semin Oncol 9:65-74, 1982

Monto RW , Talley RW , Caldwell MJ , et al: Observations on the mechanism of hemorrhagic toxicity in mithramycin (NSC-24559) therapy. Cancer Res 29:697-704, 1969

McClay E. , Lusch CJ , Mastrangelo MJ : Allergy-induced hepatic toxicity associated with dacarbazine. Cancer Treat Rep 71:219-220,1987

Greenstone MA , Dowd PM , Mikhailidis DP , et al: Hepatic vascular lesions associated with dacarbazine treatment. Br Med J 282:1744-1745, 1982

Ceci G. , Bella M. , Melissari M. , et al: Fatal hepatic vascular toxicity of DTIC: Is it really a rare event? Cancer 61:1988 -1991,1988

DeVita VT , Carbone PP , Owens AH , et al: Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962 . Cancer Res 25:1876-1881, 1965

Bacon AM , Rosenberg SA : Cyclophosphamide hepatotoxicity in a patient with systemic lupus erythematosus . Ann Intern Med 97:62-63, 1982

D'Angio GJ : Hepatotoxicity with actinomycin D. Lancet 2:104, 1987 (lettr)

Slavin RE , Dias MA , Saral R. : Cytosine arabinoside-induced gastrointestinal toxic alterations in sequential chemotherapeutic protocols. Cancer 42:1747-1759, 1978

Pratt CB , Johnson WW : Duration and severity of fatty metamorphosis of the liver following L-asparaginase therapy. Cancer 28:361-364, 1971

Kaplan RS , Wiernik PH : Neurotoxicity of antineoplastic agents. Semin Oncol 9:103-130, 1982

Legha SS , Dimery IW : High-dose cisplatin administration without hypertonic saline: Observation of disabling neurotoxicity. J Clin Oncol 3:1373-1378, 1985

Hadley D. , Herr HW : Peripheral neuropathy associated with cis-dichlorodiammine platinum (II) treatment . Cancer 44:2026-2028, 1979

Trugman J. , Hogenkamp HP , Roelofs R. , et al: Cisplatin neurotoxicity: Failure to demonstrate vitamin B12 inactivation. Cancer Treat Rep 69:453-455, 1985

VonHoff DD , Schilsky R. , Reichert CM , et al: Toxic effects of Cis-dichlorodiammineplatinum (II) in man. Cancer Treat Rep 63:1527-1531, 1979

Piel JJ , Meyer D. , Perlia CP , et al: Effects of Cis-diamminedichloroplatinum (NSC-119875) on hearing function in man. Cancer Chemother Rep 58:871-875, 1974

Fleming S. , Peppard S. , Ratanatharathorn V. , et al: Ototoxicity from cis-platinum in patients with stages III and IV previously untreated squamous cell cancer of the head and neck. Am J Clin Oncol 8:302-306, 1985

Wilding G. , Caruso R. , Lawrence TS , et al: Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol 3:1683-1689, 1985

Aass N. , Kaasa S. , Lund E. , et al: Long-term somatic side-effects and morbidity in testicular cancer patients. Br J Cancer 61:151-155, 1990

Cowan JD , Kies MS , Roth JL , et al: Nerve conduction studies in patients treated with cis-diamminedichloroplatinum (II): A preliminary report. Cancer Treat Rep 64:1119-1122,1980

Schaefer SD , Post JD , Close LG , et al: Ototoxicity of low- and moderate-dose cisplatin. Cancer 56:1934-1939, 1985

Reed E. , Kohn KW : Platinum analogues, in Chabner BA , Collins JM (eds): Cancer Chemotherapy Principles and Practice. Philadelphia, PA, Lippincott, 1990, pp 456-490

Granowetter L. , Rosenstock JG , Packer RJ : Enhanced cis-platinum neurotoxicity in pediatric patients with brain tumors. J Neurooncol 1:293-297, 1983

Schweitzer VG , Rarey KE , Dolan DF , et al: Ototoxicity of cisplatin vs. platinum analogs CBDCA (JM-8) and CHIP (JM-9). Otolaryngol Head Neck Surg 94:458-470, 1986

Whitelaw DM , Cowan DH , Cassidy FR , et al: Clinical experience with vincristine . Cancer Chemother Rep 30:13-20, 1963

Desai ZR , Van den Berg HW , Bridges JM , et al: Can severe vincristine neurotoxicity be prevented? Cancer Chemother Pharmacol 8:211-214, 1982

Bender RA , Hamel E. , Hande KR : Plant alkaloids, in Chabner BA , Collins JM (eds): Cancer Chemotherapy Principles and Practice. Philadelphia, PA, Lippincott, 1990, pp 253-275

Sandler SG , Tobin W. , Henderson ES : Vincristine-induced neuropathy: A clinical study of fifty leukemic patients. Neurology 19:367-374, 1969

Casey EB , Jellife AM , LeQuesne PM , et al: Vincristine neuropathy: Clinical and electrophysiological observations . Brain 96:69-86, 1973

Weiss HD , Walker MD , Wiernik PH : Neurotoxicity of commonly used antineoplastic agents. N Engl J Med 291:71-81, 127-133, 1974

Holland JF , Scharlav C. , Gailani S. , et al: Vincristine treatment of advanced cancer: A cooperative study of 392 cases. Cancer Res 33:1258-1264,1973

Rosenthal S. , Kaufman S. : Vincristine neurotoxicity. Ann Intern Med 80:733-737, 1974

Cassady JR , Tonnesen GL , Wolfe LC , et al: Augmentation of vincristine neurotoxicity by irradiation of peripheral nerves. Cancer Treat Rep 64:963-965, 1980

Taylor SG , Desai SA , DeWys WD : Phase II trial of a combination of cyclophosphamide, vincristine, and methotrexate in advanced colorectal cancer. Cancer Treat Rep 62:1203-1205,1978

Griffiths JD , Stark RJ , Ding JC , et al: Vincristine neurotoxicity enhanced in combination chemotherapy including both teniposide and vincristine. Cancer Treat Rep 70:519-521, 1986

Bradley WG , Lassman LP , Pearce GW , et al: The neuropathy of vincristine in man: Clinical, electrophysiological, and pathological studies . J Neurol Sci 10:107-131, 1970

Finley RS , Fortner CL , Grove WR : Cisplatin nephrotoxicity: A summary of preventative interventions . Drug Intell Clin Pharm 19:362-367, 1985

Gonzales-Vitale JC , Hayes DM , Cvitkovic E. , et al: The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 39:1362-1371, 1977

Groth S. , Nielsen H. , Sørensen JB , et al: Acute and long-term nephrotoxicity of cis-platinum in man. Cancer Chemother Pharmacol 17:191-196,1986

Dentino M. , Luft FC , Yum MN , et al: Long-term effect of cis-diammine-dichloroplatinum (CDDP) on renal function and structure in man. Cancer 41:1224-1281, 1978

Blachley JD , Hill JB : Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med 95:628-632, 1981

Hutchison FN , Perez EA , Gandara DR , et al: Renal salt wasting in patients treated with cisplatin. Ann Intern Med 108:21-25, 1988

Jones BR , Bhalla RB , Mladek J. , et al: Comparison of methods of evaluating nephrotoxicity of cis-platinum . Clin Pharmacol Ther 27:557-562, 1980

Meijer S. , Sleisfer D. , Mulder NH , et al: Some effects of combination chemotherapy with cis-platinum on renal function in patients with non seminomatous testicular carcinoma. Cancer 51:2035-2040, 1983

Bodenner DL , Dedon PC , Keng PC , et al: Effect of diethyldithiocarbamate on cis-diamminedichloroplatinum(II)-induced cytotoxicity, DNA cross-linking, and gamma-glutamyl transpeptidase inhibition. Cancer Res 46: 2745-2750,1986

Dedon PC , Borch RJ : Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles. Biochem Pharmacol 36:1955 -1964,1987

Nanji AA , Stewart DJ , Mikhael NZ : Hyperuricemia and hypoalbuminemia predispose to cisplatin-induced nephrotoxicity . Cancer Chemother Pharmacol 17:274-276, 1986 167. Kelsen DP , Alcock N. , Young CW : Cisplatin nephrotoxicity: Correlation with plasma platinum concentration. Am J Clin Oncol 8:77-80, 1985

Ozols RF , Corden BJ , Jacob J. , et al: High-dose cisplatin in hypertonic saline. Ann Intern Med 100:19-24, 1984

Salem P. , Khatyl M. , Jabboury K. , et al: Cis-diamminedichloroplatinum (II) by 5-day continuous infusion. A new dose schedule with minimal toxicity. Cancer 53:837-840,1984

Schilsky RL : Renal and metabolic toxicities of cancer chemotherapy . Semin Oncol 9:75-83, 1982

Pera MF , Harder HD : Effects of mannitol or furosemide diuresis on the nephrotoxicity and physiological disposition of cis-dichlorodiammineplatinum (II) in rats. Cancer Res 39:1269-1278,1979

Glover DJ , Glick JH , Weiler C. , et al: WR-2721 and high dose cisplatin: An active combination in metastatic melanoma. J Clin Oncol 5:574-578,1987

Glover D. , Glick J. , Weiler C. , et al: Phase I/II trials of WR-2721 and cis-platinum. Int J Radiat Oncol Biol Physiol 12:1509-1512,1986

Pitman SW , Parker LM , Tatersall Mhn , et al: Clinical trial of high dose methotrexate (NSC740) with citrovorum factor (NSC3590): Toxicologic and therapeutic observations. Cancer Chemother Rep 6:43-49, 1975

Condit PT , Chanes RE , Joel W. : Renal toxicity of methotrexate. Cancer 23:126-131, 1969

Ackland SP , Schilsky RL : High-dose methotrexate: A critical reappraisal . J Clin Oncol 5:2017-2031, 1987

Jacobs SA , Stoller RG , Chabner BA , et al: 7-Hydroxy methotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high-dose methotrexate. J Clin Invest 57:534-538, 1976

Taylor SG , McGuire WP , Hauck WW , et al: A randomized comparison of high-dose infusion methotrexate versus standard-dose weekly therapy in head and neck squamous cancer. J Clin Oncol 2:1006-1011, 1984

Ettinger DS , Stanley KE , Nystrom JS : Phase II study of high-dose methotrexate in the treatment of patients with non-small cell carcinoma of the lung: An Eastern Cooperative Oncology Group study. Cancer Treat Rep 64:1017-1021, 1980

Schacht RG , Feiner HD , Gallo GR , et al: Nephrotoxicity of nitrosoureas. Cancer 48:1328-1334, 1981

Harmon WE , Cohen HJ , Schneeberger EE , et al: Chronic renal failure in children treated with methyl CCNU. N Engl J Med 300:1200-1203,1979

Silver Hkb , Morton DL : CCNU nephrotoxicity following sustained remission in oat cell carcinoma. Cancer Treat Rep 63:226-227, 1979

Micetich K. , Jensen-Akula M. , Mandard J. , et al: Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy. Am J Med 71:967-972,1981

Moertel CG , Reitemeier RJ , Schutt AJ , et al: Phase II study of streptozotocin in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 55:303-307, 1981

Fennell JS , Falls WF Jr : Streptozotocin nephrotoxicity: Studies on the defect in renal tubular acidification. Clin Nephrol 15:97-101, 1981

DeFronzo RA , Braine HG , Colvin M. , et at: Water intoxication in man after cyclophosphamide therapy. Ann Intern Med 78:861-869,1973

DeFronzo RA , Colvin OM , Braine H. , et al: Cyclophosphamide and the kidney. Cancer 33:483-491, 1974

Hsu HC , Tsai HM : Cyclophosphamide induced glomerular injury in newborn mice. Lab Invest 47:281-285, 1982

Ravikumar TS , Sibley R. , Reed R. , et al: Renal toxicity of mitomycin C. Am J Clin Oncol 7:279-285, 1984

Hanna WT , Krauss S. , Regester RF , et al: Renal disease after mitomycin C therapy. Cancer 48:2583-2588, 1981

Woloschuk D. , Preumer JM , Cluxton RJ : Carboplatin: A new cisplatin analog. Drug Intell Clin Pharm 22:843-849, 1988

Reed E. , Jacob J. : Carboplatin and renal dysfunction. Ann Intern Med 110:409, 1989 (lettr)

Cox PJ : Cyclophosphamide cystitis-identification of acrolein as the causative agent . Biochem Pharmacol 28:2045-2049, 1979

Rubin JS , Rubin RT : Cyclophosphamide hemorrhagic cystitis. J Urol 96:313-316, 1966

Buzdar AV , Legha SS , Tashima CK , et al: Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast carcinoma. Cancer Treat Rep 63:115-119,1979

Colvin M. , Chabner BA : Alkylating agents, in Chabner BA , Collins JM (eds): Cancer Chemotherapy Principles and Practice. Philadelphia, PA, Lippincott, 1990, pp 276-313

Andriole GL , Sandlund JT , Miser JS , et al: The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy . J Clin Oncol 5:799-803, 1987

Shrom SH , Donaldson MH , Ducket JW , et al: Formalin treatment for intractable hemorrhagic cystitis. Cancer 38:1785-1789, 1976

Ehrlich RM , Freedman A. , Goldsobel AB , et al: The use of sodium 2-mercaptoethane sulfonate to prevent cyclophosphamide cystitis. J Urol 131:960-962, 1984

Primack A. : Amelioration of cyclophosphamide-induced cystitis . J Natl Cancer Inst 47:223-227, 1971

Jackson H. , Fox BW , Craig AW : Antifertility substances and their assessment in the male rodent. J Reprod Fertil 2:447-465, 1961

Jackson H. : The effects of alkylating agents on fertility . Br Med Bull 20:107-114, 1964

Lu CC , Meistrich ML : Cytotoxic effects of chemotherapeutic drugs on mouse testis cells . Cancer Res 39:3575-3582,1979

Meistrich ML , Finch M. , da Cunha MF , et al: Damaging effects of fourteen chemotherapeutic drugs on mouse testis cells. Cancer Res 42:122-131, 1982

Fairley KF , Barrie JU , Johnson W. : Sterility and testicular atrophy related to cyclophosphamide therapy. Lancet 1:568-569, 1972

Richter P. , Calamera JC , Morgenfeld MC , et al: Effect of chlorambucil on spermatogenesis in the human with malignant lymphoma. Cancer 25:1026-1030, 1970

Mecklenberg RS , Sherins RJ : Gonadotropin response to luteinizing hormone releasing hormone in men with germinal aplasia. J Clin Endocrinol Metab 38:1005-1009, 1974

Whitehead E. , Shalet SM , Blackledge G. , et al: The effects of Hodgkin's disease and combination chemotherapy on gonadal function in the adult male. Cancer 49:418-422, 1982

Sherins RJ , DeVita VT : Effects of drug treatment for lymphoma on male reproductive capacity. Ann Intern Med 79:216-220,1976

da Cunha MF , Meistrich ML , Fuller ML , et al: Recovery of spermatogenesis after treatment for Hodgkin's disease: Limiting dose of MOPP chemotherapy. J Clin Oncol 2:571-577, 1984

Miller JJ , Williams GF , Leissring JC : Multiple late complications of therapy with cyclophosphamide including ovarian destruction. Am J Med 50:530-535, 1971

Schilsky RL , Erlichman C. : Infertility and carcinogenesis: Late complications of chemotherapy , in Chabner BA , Collins JM (eds): Cancer Chemotherapy Principles and Practice . Philadelphia, PA, Lippincott , 1990, pp 32-58

Siris EJ , Leventhal BG , Vaitukaitis JL : Effects of childhood leukemia and chemotherapy on pubert and reproductive function in girls. N Engl J Med 294:1143-1146, 1976

Henne T. , Schmähl D. : Occurrence of second primary malignancies in man—a second look . Cancer Treat Rev 12:77-94, 1985

Kushner BH , Zauber A. , Tan Ctc : Second malignancies after childhood Hodgkin's disease: The Memorial Sloan-Kettering Cancer Center experience. Cancer 62:1364-1370,1988

Fraser MC , Tucker MA : Late effects of cancer therapy: Chemotherapy-related malignancies . Oncol Nurs Forum 15:67-77, 1988

Pedersen-Bjergaard J. , Larsen SO : Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. N Engl J Med 307:965-971, 1982

Bradley EC , Schechter GP , Matthews MJ : Erythroleukemia and other hematologic complications of intensive therapy in long-term survivors of small cell lung cancer. Cancer 49:221-223, 1982

Pedersen-Bjergaard J. , Ersbøll J. , Sørensen HM , et al: Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Ann Intern Med 103:195-200, 1985

Pui CH , Behm FG , Raimondi SC , et al: Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med 321:136-142, 1989

Greene MH , Boice JD , Greer BE , et al: Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer. N Engl J Med 307:1416-1421, 1982

Boice JD , Greene MH , Killen JY , et al: Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N Engl J Med 309:1079-1084,1983

Reimer RR , Hoover R. , Fraumeni JF , et al: Acute leukemia after alkylating-agent therapy of ovarian cancer . N Engl J Med 177-181, 1977

Tucker MA , Coleman CN , Cox RS , et al: Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 318:76-81, 1988

Pedersen-Bjergaard J. , Ersbøll J. , Hansen VL , et al: Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med 318:1028-1032, 1988

Seidenfeld AM , Smyth HA , Ogryzlo MA , et al: Acute leukemia in rheumatoid arthritis treated with cytotoxic agents. J Rheumatol 3:295-304, 1976

Baker GL , Kahl LE , Zee BC , et al: Malignancy following treatment of rheumatoid arthritis with cyclophosphamide . Am J Med 83:1-9,1987

Helm F. , Helm TN : Iatrogenic myelomonocytic leukemia following melphalan treatment of scleromyxedema . Cutis 39:219-223, 1987

Boivin JF : Second cancers and other late side effects of cancer treatment: A review. Cancer 65:770-775, 1990

Greene MH , Harris EL , Gershenson DM , et al: Melphalan may be a more potent leukemogen than cyclophosphamide . Ann Intern Med 105:360-367, 1986